Research Report on China's Levetiracetam Market, 2021-2025
我國癲癇患病率約為7□，估計我國癲癇患者至少有900萬。我國60%以上的癲癇患者為兒童或青少年，且癲癇長期復發，嚴重損害患者身心健康，給患者家庭和社會帶來沉重負擔。近年來，我國人口老齡化加劇，腦血管病、癡呆、神經退行性疾□□病的發病率呈上升趨勢。尤其是50歲以上老年人的癲癇發病率呈上升趨勢。中國每年約有 40 萬新病例。癲癇患者的數量每年持續快速增長，給個人、家庭和社會帶來嚴重後果。
目前，癲癇以藥物治療為主，但據說有70%左右的患者只要按照規範用藥，就能控制好自己的病情。Levetiracetam最初由 UCB Pharma 開發，商品名為 "Keppra" 。Levetiracetam於1999年首次在美國上市，作為治療癲癇的一線藥物，緩釋片於2008年獲得FDA批准，現在被廣泛稱為治療癲癇的金標準。
Keppra 於 2006 年 11 月獲准在中國銷售。 2009年，專利到期後，仿製藥被中國企業銷售，但Keppra仍佔據大部分市場份額。Levetiracetam的劑型包括片劑、口服溶液和注射劑。其中，Levetiracetam片佔有主要市場份額，最激烈的市場競爭是仿製藥的增加。
Epilepsy is second only to stroke as a common chronic neurological disorder characterized by excessive neuronal discharge in the brain resulting in recurrent, seizure and transient central nervous system malfunctions. Epilepsy occurs in people of any age, region, and race, especially in children and adolescents.
The prevalence of epilepsy in China is approximately 7‰, based on which the number of people with epilepsy in China is estimated to be no less than 9 million. More than 60% of Chinese epilepsy patients are children and adolescents, and because of the long and recurrent course of epilepsy, the physical and mental health of patients is seriously threatened, which brings a heavy burden to families and society. In recent years, as China's population ages, the incidence of cerebrovascular disease, dementia, and neurodegenerative diseases has increased. Particularly, the incidence of epilepsy has been on the rise in the elderly population over the age of 50. Approximately there are 400,000 new cases in China each year. Since the number of people with epilepsy is still growing at a faster rate each year, individuals, families and society will be seriously affected.
At present, epilepsy is mainly treated with medication, and if epilepsy patients use medication in a standardized way, about 70% of them can have their condition well controlled.
Levetiracetam was first developed by UCB under the trade name of Keppra®. As a first-line drug in the field of epilepsy treatment, levetiracetam was first marketed in the United States in 1999 in tablet form, and the extended-release tablet form was approved by the FDA in 2008, which is now widely regarded as the gold standard drug for epilepsy treatment.
Keppra was approved for marketing in China in November 2006. In 2009, after the expiration of the patent, generic drugs by Chinese companies were marketed, but Keppra still occupied a major market share. The dosage forms of levetiracetam include tablet, oral solution and injection. Among them, levetiracetam tablets have the main market share and the fiercest market competition with increasing generic drugs.
According to CRI's market research, the sales value of levetiracetam in the Chinese market continued to rise from 2016 to 2019. In 2020, the COVID-19 outbreak prevented Chinese healthcare facilities from functioning properly. And as the various dosage forms of levetiracetam are prescription drugs in China, the total sales value of levetiracetam declined to approximately CNY319 million (USD49.1 million) with a CAGR of approximately 2.3% from 2016 to 2020.
CRI expects that from 2021 to 2025, China's levetiracetam market will show a recovery growth in both sales volume and value due to the effective control of COVID-19 and the resumption of proper operation of healthcare facilities. The number of patients with epilepsy in China will continue to rise because of factors such as the accelerated pace of life and work and poor lifestyle behaviors like late nights, alcohol abuse, and the increasingly aging population, driving up both sales volume and value of levetiracetam in the Chinese market.
Impact of COVID-19 on China's Levetiracetam Market
Development Environment of Levetiracetam in China
Sales Volume of Levetiracetam in China
Sales Volume and Value of Levetiracetam in China by Region
Major Levetiracetam Manufacturers in China and Their Market Shares
Sales Price of Levetiracetam in China
Prospects of China's Levetiracetam Market, 2021-2025